Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

Yu Yang; Juxian Sun; Mengchao Wu; Wan Yee Lau; Shusen Zheng; Xue Hao Wang; Xiaoping Chen; Jia Fan; Jiahong Dong; Jianqiang Cai; Minshan Chen; Yongjun Chen; Zhangjun Cheng; Chaoliu Dai; Jianzhen Shan; Cheng You Du; Chihua Fang; Heping Hu; Zhili Ji; Weidong Jia; Gong Li; Jing Li; Jiangtao Li; Chang Liu; Fubao Liu; Yong Ma; Yilei Mao; Zuoxing Niu; Jie Shen; Jie Shi; Xuetao Shi; Wenjie Song; Hui Chuan Sun; Guang Tan; Ran Tao; Xiaohu Wang; Tianfu Wen; Liqun Wu; Jinglin Xia; Bang De Xiang; Maolin Yan; Mingang Ying; Ling Zhang; Xuewen Zhang; Zhao Chong Zeng; Yubao Zhang; Zhiwei Zhang; Jie Zhou; Cuncai Zhou; Jun Zhou; Ledu Zhou; Xinmin Zhou; Ji Zhu; Zhenyu Zhu; Qi Zhang; Qiu Li; Shuqun Cheng

doi:10.1159/000526038

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

Yu Yang
, Juxian Sun
, Mengchao Wu
, Wan Yee Lau
, Shusen Zheng
, Xue Hao Wang
, Xiaoping Chen
, Jia Fan
, Jiahong Dong
, Jianqiang Cai
, Minshan Chen
, Yongjun Chen
, Zhangjun Cheng
, Chaoliu Dai
, Jianzhen Shan
, Cheng You Du
, Chihua Fang
, Heping Hu
, Zhili Ji
, Weidong Jia

Gong Li, Jing Li, Jiangtao Li, Chang Liu, Fubao Liu, Yong Ma, Yilei Mao, Zuoxing Niu, Jie Shen, Jie Shi, Xuetao Shi, Wenjie Song, Hui Chuan Sun, Guang Tan, Ran Tao, Xiaohu Wang, Tianfu Wen, Liqun Wu, Jinglin Xia, Bang De Xiang, Maolin Yan, Mingang Ying, Ling Zhang, Xuewen Zhang, Zhao Chong Zeng, Yubao Zhang, Zhiwei Zhang, Jie Zhou, Cuncai Zhou, Jun Zhou, Ledu Zhou, Xinmin Zhou, Ji Zhu, Zhenyu Zhu, Qi Zhang, Qiu Li, Shuqun Cheng

Sichuan University
Naval Medical University
Chinese University of Hong Kong
Shulan (Hangzhou) Hospital
The First Affiliated Hospital with Nanjing Medical University
Huazhong University of Science and Technology
Fudan University
Tsinghua University
Chinese Academy of Medical Sciences
Sun Yat-Sen University Cancer Center
Shanghai Jiao Tong University
Southeast University, Nanjing
China Medical University
Zhejiang University School of Medicine
First Affiliated Hospital of Chongqing Medical University
Southern Medical University
Capital Medical University
University of Science and Technology of China
Army Medical University
The Second Affiliated Hospital of Zhejiang University School of Medicine
The First Affiliated Hospital of Xi’an Jiaotong University
Anhui Medical University
The First Affiliated Hospital of Harbin Medical University
Shandong Cancer Hospital
Nanjing University
Xijing Hospital
Dalian Medical University
Zhejiang Provincial People's Hospital
Gansu Cancer Hospital
Qingdao University
Guangxi Medical University
Fujian Provincial Hospital
Fujian Medical University
Zhengzhou University
Jilin University
Harbin Medical University
Jiangxi Provincial Cancer Hospital
Peking University
Central South University
University of Chinese Academy of Sciences
General Hospital of People's Liberation Army
The Third Affiliated Hospital of Sun Yat-sen University

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)"based on current clinical studies and clinical medication experience for reference in China. Key Messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

Original language	English
Pages (from-to)	511-526
Number of pages	16
Journal	Liver Cancer
Volume	11
Issue number	6
DOIs	https://doi.org/10.1159/000526038
State	Published - 20 Dec 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Consensus
Hepatocellular carcinoma
Immune checkpoint inhibitors

Access to Document

10.1159/000526038

Cite this

@article{f7e6768d41034846b6ba464f73dfce6a,

title = "Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)",

abstract = "Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the {"}Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021){"}based on current clinical studies and clinical medication experience for reference in China. Key Messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.",

keywords = "Consensus, Hepatocellular carcinoma, Immune checkpoint inhibitors",

author = "Yu Yang and Juxian Sun and Mengchao Wu and Lau, \{Wan Yee\} and Shusen Zheng and Wang, \{Xue Hao\} and Xiaoping Chen and Jia Fan and Jiahong Dong and Jianqiang Cai and Minshan Chen and Yongjun Chen and Zhangjun Cheng and Chaoliu Dai and Jianzhen Shan and Du, \{Cheng You\} and Chihua Fang and Heping Hu and Zhili Ji and Weidong Jia and Gong Li and Jing Li and Jiangtao Li and Chang Liu and Fubao Liu and Yong Ma and Yilei Mao and Zuoxing Niu and Jie Shen and Jie Shi and Xuetao Shi and Wenjie Song and Sun, \{Hui Chuan\} and Guang Tan and Ran Tao and Xiaohu Wang and Tianfu Wen and Liqun Wu and Jinglin Xia and Xiang, \{Bang De\} and Maolin Yan and Mingang Ying and Ling Zhang and Xuewen Zhang and Zeng, \{Zhao Chong\} and Yubao Zhang and Zhiwei Zhang and Jie Zhou and Cuncai Zhou and Jun Zhou and Ledu Zhou and Xinmin Zhou and Ji Zhu and Zhenyu Zhu and Qi Zhang and Qiu Li and Shuqun Cheng",

note = "Publisher Copyright: {\textcopyright} 2022 ",

year = "2022",

month = dec,

day = "20",

doi = "10.1159/000526038",

language = "英语",

volume = "11",

pages = "511--526",

journal = "Liver Cancer",

issn = "2235-1795",

publisher = "S. Karger AG",

number = "6",

}

Yang, Y, Sun, J, Wu, M, Lau, WY, Zheng, S, Wang, XH, Chen, X, Fan, J, Dong, J, Cai, J, Chen, M, Chen, Y, Cheng, Z, Dai, C, Shan, J, Du, CY, Fang, C, Hu, H, Ji, Z, Jia, W, Li, G, Li, J, Li, J, Liu, C, Liu, F, Ma, Y, Mao, Y, Niu, Z, Shen, J, Shi, J, Shi, X, Song, W, Sun, HC, Tan, G, Tao, R, Wang, X, Wen, T, Wu, L, Xia, J, Xiang, BD, Yan, M, Ying, M, Zhang, L, Zhang, X, Zeng, ZC, Zhang, Y, Zhang, Z, Zhou, J, Zhou, C, Zhou, J, Zhou, L, Zhou, X, Zhu, J, Zhu, Z, Zhang, Q, Li, Q & Cheng, S 2022, 'Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)', Liver Cancer, vol. 11, no. 6, pp. 511-526. https://doi.org/10.1159/000526038

TY - JOUR

T1 - Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

AU - Yang, Yu

AU - Sun, Juxian

AU - Wu, Mengchao

AU - Lau, Wan Yee

AU - Zheng, Shusen

AU - Wang, Xue Hao

AU - Chen, Xiaoping

AU - Fan, Jia

AU - Dong, Jiahong

AU - Cai, Jianqiang

AU - Chen, Minshan

AU - Chen, Yongjun

AU - Cheng, Zhangjun

AU - Dai, Chaoliu

AU - Shan, Jianzhen

AU - Du, Cheng You

AU - Fang, Chihua

AU - Hu, Heping

AU - Ji, Zhili

AU - Jia, Weidong

AU - Li, Gong

AU - Li, Jing

AU - Li, Jiangtao

AU - Liu, Chang

AU - Liu, Fubao

AU - Ma, Yong

AU - Mao, Yilei

AU - Niu, Zuoxing

AU - Shen, Jie

AU - Shi, Jie

AU - Shi, Xuetao

AU - Song, Wenjie

AU - Sun, Hui Chuan

AU - Tan, Guang

AU - Tao, Ran

AU - Wang, Xiaohu

AU - Wen, Tianfu

AU - Wu, Liqun

AU - Xia, Jinglin

AU - Xiang, Bang De

AU - Yan, Maolin

AU - Ying, Mingang

AU - Zhang, Ling

AU - Zhang, Xuewen

AU - Zeng, Zhao Chong

AU - Zhang, Yubao

AU - Zhang, Zhiwei

AU - Zhou, Jie

AU - Zhou, Cuncai

AU - Zhou, Jun

AU - Zhou, Ledu

AU - Zhou, Xinmin

AU - Zhu, Ji

AU - Zhu, Zhenyu

AU - Zhang, Qi

AU - Li, Qiu

AU - Cheng, Shuqun

PY - 2022/12/20

Y1 - 2022/12/20

N2 - Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)"based on current clinical studies and clinical medication experience for reference in China. Key Messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

AB - Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)"based on current clinical studies and clinical medication experience for reference in China. Key Messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

KW - Consensus

KW - Hepatocellular carcinoma

KW - Immune checkpoint inhibitors

UR - https://www.scopus.com/pages/publications/85143904701

U2 - 10.1159/000526038

DO - 10.1159/000526038

M3 - 文献综述

AN - SCOPUS:85143904701

SN - 2235-1795

VL - 11

SP - 511

EP - 526

JO - Liver Cancer

JF - Liver Cancer

IS - 6

ER -

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this